Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 4, 10, 3 and 1 respectively.
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 4, 10, 3 and 1 respectively.
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
ADARx Pharmaceuticals Inc
Astria Therapeutics Inc
Attune Pharmaceuticals
BioMarin Pharmaceutical Inc
Bioviz Technologies Pvt Ltd
Bridge Medicines LLC
CAMP4 Therapeutics Corp
CSL Ltd
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Octapharma AG
Pharming Group NV
Pharvaris NV
Ractigen Therapeutics Inc
Spark Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Verseon Corp
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
ADX-324 - Drug Profile
Product Description
Mechanism Of Action
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
BMN-331 - Drug Profile
Product Description
Mechanism Of Action
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
conestat alfa - Drug Profile
Product Description
Mechanism Of Action
donidalorsen sodium - Drug Profile
Product Description
Mechanism Of Action
garadacimab - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
Haegarda - Drug Profile
Product Description
Mechanism Of Action
IONIS-PKKRx - Drug Profile
Product Description
Mechanism Of Action
KV-998052 - Drug Profile
Product Description
Mechanism Of Action
KV-998054 - Drug Profile
Product Description
Mechanism Of Action
KV-998086 - Drug Profile
Product Description
Mechanism Of Action
KVD-998083 - Drug Profile
Product Description
Mechanism Of Action
lanadelumab - Drug Profile
Product Description
Mechanism Of Action
NTLA-2002 - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides to Activate SERPING1 for Hereditary Angioedema (HAE) - Drug Profile
Product Description
Mechanism Of Action
OTL-105 - Drug Profile
Product Description
Mechanism Of Action
PHVS-416 - Drug Profile
Product Description
Mechanism Of Action
PHVS-719 - Drug Profile
Product Description
Mechanism Of Action
RAG-12 - Drug Profile
Product Description
Mechanism Of Action
sebetralstat - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Factor XII for Hereditary Angioedema and Inflammation - Drug Profile
Product Description
Mechanism Of Action
STAR-0215 - Drug Profile
Product Description
Mechanism Of Action
VE-4062 - Drug Profile
Product Description
Mechanism Of Action
VE-4666 - Drug Profile
Product Description
Mechanism Of Action
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2022: Takeda receives prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO (lanadelumab)
Nov 14, 2022: Intellia Therapeutics to present updated interim clinical data from ongoing phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 ACAAI Annual Scientific Meeting
Nov 13, 2022: Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Nov 12, 2022: Intellia Therapeutics presents new interim data from first-in-human study of NTLA-2002 for the treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Nov 07, 2022: Astria Therapeutics to present STAR-0215 modeling and simulation data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
Oct 31, 2022: KalVista Pharmaceuticals announces positive phase 1 data for orally disintegrating tablet formulation of sebetralstat for use in hereditary angioedema
Oct 19, 2022: KalVista Pharmaceuticals announces publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
Oct 07, 2022: KalVista Pharmaceuticals presents new patient-centric data at 2022 HAEi Global Leadership Workshop
Oct 05, 2022: U.S. Food and Drug Administration accepts Takeda’s Supplemental Biologics License Application for use of TAKHZYRO (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in children 2 years of age and older
Sep 30, 2022: Astria Therapeutics to host virtual R&D Day: update on STAR-0215 and its clinical development
Sep 16, 2022: Intellia Therapeutics announces positive interim clinical data for its second systemically delivered investigational CRISPR candidate, NTLA-2002 for the treatment of hereditary angioedema (HAE)
Sep 16, 2022: Intellia Therapeutics to present interim clinical data from ongoing phase 1/2 study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 Bradykinin Symposium
Sep 16, 2022: Intellia Therapeutics announces upcoming investor event to present interim clinical data from ongoing first-in-human studies of NTLA-2002 on September 16, 2022
Sep 01, 2022: Intellia Therapeutics receives U.S. FDA orphan drug designation for NTLA-2002, an investigational CRISPR therapy for the treatment of Hereditary Angioedema
Aug 23, 2022: KalVista Pharmaceuticals announces initiation of KONFIDENT-S open label extension study for sebetralstat in hereditary angioedema
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
ADARx Pharmaceuticals Inc
Astria Therapeutics Inc
Attune Pharmaceuticals
BioMarin Pharmaceutical Inc
Bioviz Technologies Pvt Ltd
Bridge Medicines LLC
CAMP4 Therapeutics Corp
CSL Ltd
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Octapharma AG
Pharming Group NV
Pharvaris NV
Ractigen Therapeutics Inc
Spark Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Verseon Corp
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
ADX-324 - Drug Profile
Product Description
Mechanism Of Action
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
BMN-331 - Drug Profile
Product Description
Mechanism Of Action
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
conestat alfa - Drug Profile
Product Description
Mechanism Of Action
donidalorsen sodium - Drug Profile
Product Description
Mechanism Of Action
garadacimab - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
Haegarda - Drug Profile
Product Description
Mechanism Of Action
IONIS-PKKRx - Drug Profile
Product Description
Mechanism Of Action
KV-998052 - Drug Profile
Product Description
Mechanism Of Action
KV-998054 - Drug Profile
Product Description
Mechanism Of Action
KV-998086 - Drug Profile
Product Description
Mechanism Of Action
KVD-998083 - Drug Profile
Product Description
Mechanism Of Action
lanadelumab - Drug Profile
Product Description
Mechanism Of Action
NTLA-2002 - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides to Activate SERPING1 for Hereditary Angioedema (HAE) - Drug Profile
Product Description
Mechanism Of Action
OTL-105 - Drug Profile
Product Description
Mechanism Of Action
PHVS-416 - Drug Profile
Product Description
Mechanism Of Action
PHVS-719 - Drug Profile
Product Description
Mechanism Of Action
RAG-12 - Drug Profile
Product Description
Mechanism Of Action
sebetralstat - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Factor XII for Hereditary Angioedema and Inflammation - Drug Profile
Product Description
Mechanism Of Action
STAR-0215 - Drug Profile
Product Description
Mechanism Of Action
VE-4062 - Drug Profile
Product Description
Mechanism Of Action
VE-4666 - Drug Profile
Product Description
Mechanism Of Action
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2022: Takeda receives prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO (lanadelumab)
Nov 14, 2022: Intellia Therapeutics to present updated interim clinical data from ongoing phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 ACAAI Annual Scientific Meeting
Nov 13, 2022: Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Nov 12, 2022: Intellia Therapeutics presents new interim data from first-in-human study of NTLA-2002 for the treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Nov 07, 2022: Astria Therapeutics to present STAR-0215 modeling and simulation data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
Oct 31, 2022: KalVista Pharmaceuticals announces positive phase 1 data for orally disintegrating tablet formulation of sebetralstat for use in hereditary angioedema
Oct 19, 2022: KalVista Pharmaceuticals announces publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
Oct 07, 2022: KalVista Pharmaceuticals presents new patient-centric data at 2022 HAEi Global Leadership Workshop
Oct 05, 2022: U.S. Food and Drug Administration accepts Takeda’s Supplemental Biologics License Application for use of TAKHZYRO (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in children 2 years of age and older
Sep 30, 2022: Astria Therapeutics to host virtual R&D Day: update on STAR-0215 and its clinical development
Sep 16, 2022: Intellia Therapeutics announces positive interim clinical data for its second systemically delivered investigational CRISPR candidate, NTLA-2002 for the treatment of hereditary angioedema (HAE)
Sep 16, 2022: Intellia Therapeutics to present interim clinical data from ongoing phase 1/2 study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 Bradykinin Symposium
Sep 16, 2022: Intellia Therapeutics announces upcoming investor event to present interim clinical data from ongoing first-in-human studies of NTLA-2002 on September 16, 2022
Sep 01, 2022: Intellia Therapeutics receives U.S. FDA orphan drug designation for NTLA-2002, an investigational CRISPR therapy for the treatment of Hereditary Angioedema
Aug 23, 2022: KalVista Pharmaceuticals announces initiation of KONFIDENT-S open label extension study for sebetralstat in hereditary angioedema
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ADARx Pharmaceuticals Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Astria Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Attune Pharmaceuticals, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioMarin Pharmaceutical Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bioviz Technologies Pvt Ltd, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bridge Medicines LLC, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CAMP4 Therapeutics Corp, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Intellia Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Octapharma AG, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharvaris NV, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ractigen Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Spark Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, 2022 (Contd..1)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, 2022
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ADARx Pharmaceuticals Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Astria Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Attune Pharmaceuticals, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioMarin Pharmaceutical Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bioviz Technologies Pvt Ltd, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bridge Medicines LLC, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CAMP4 Therapeutics Corp, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Intellia Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Octapharma AG, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharvaris NV, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ractigen Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Spark Therapeutics Inc, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, 2022
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, 2022 (Contd..1)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
